Objective To evaluate changes in patient and graft survival for pediatric liver transplant recipients since 2002, and to determine if these outcomes vary by graft type (whole liver transplant, split liver transplant [SLT], and living donor liver transplant [LDLT]).
L iver transplantation provides life-saving therapy for children with end-stage liver disease. 1 Unfortunately, successful pediatric transplantation is hindered by a scarcity of suitable livers. 2 Under the current Pediatric End-stage Liver Disease (PELD) and Model for End-stage Liver Disease (MELD) system, organs are allocated to patients based on their probability of death within 90 days while awaiting transplant. This strategy means (1) the pretransplant course for most individuals is associated with significant morbidity, hospitalization, and costs, (2) delays in transplantation exacerbate long-term impairments in cognition and growth, and (3) in some instances, children die awaiting transplantation. [3] [4] [5] The use of technical variant donation, including split liver transplantation (SLT) and living donor liver transplantation (LDLT), represents a potential solution to the organ shortage. 6 Given that approximately 6000 whole livers are used for adult recipients each year, SLT for children represents an exciting opportunity to improve organ supply, shorten waitlist times, and decrease pretransplant morbidity and mortality. Evidence from studies of adult recipients suggest that outcomes after SLT have improved in recent years and may have achieved parity with whole liver transplantation (WLT). 7 However, reports on outcomes for pediatric recipients after technical variant donation, and in particular SLT, are conflicting. [8] [9] [10] Given these inconsistent findings, the purpose of our analysis was to use a large national registry to better understand the impact of allograft type on patient and graft survival for pediatric liver transplant recipients in the most recent era. Furthermore, we sought to assess whether the association between allograft type and outcomes after transplantation have changed over time and whether these effects vary by follow-up time. Finally, we wanted to better understand which factors are associated with graft failure and whether the causes of graft failure have changed in recent years.
Methods
This study used data from the Scientific Registry of Transplant Recipients (SRTR) data system that includes data on all donors, waitlisted candidates, and transplant recipients in the US, submitted by the members of the Organ Procurement and Transplantation Network and has been described elsewhere.
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The Health Resources and Services Administration, US Department of Health and Human Services, provides oversight to the activities of the Organ Procurement and Transplantation Network and SRTR contractors. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of, or interpretation by, the SRTR or the US government. We identified 5715 pediatric (age <18 years), liver-only transplant recipients who received an organ between March 1, 2002 (ie, after implementation of the PELD/MELD system) and December 31, 2015. Additionally, people were excluded for the following reasons: listed as live donor whole liver (n = 10), missing weight (n = 1), and missing cold ischemia time (n = 395; 6% of eligible individuals). Additionally, retransplanted individuals were excluded (n = 735) because there was a very low number of individuals retransplanted with technical variant grafts (n = 194 for split liver transplant; n = 35 for living donor liver transplant). No donor organs were obtained from executed prisoners or other institutionalized persons. Individuals were defined as having a SLT if they received a portion of a deceased donor graft, irrespective of whether the organ was used by 1 or 2 recipients because evidence from other studies suggests comparable graft and patient survivals, and even potentially comparable biliary strictures and vascular thromboses. 7, 8 We compared demographic (eg, age, sex, race, and insurance status) and clinical (eg, weight, PELD/MELD scores, and diagnosis) characteristics between pediatric recipients of SLT, WLT, and LDLT using c 2 tests for categorical variables and ANOVA for continuous variables.
We calculated patient and graft survival at 30 days and 1 year after SLT, WLT, or LDLT, and compared survival between allograft types using Kaplan-Meier curves and log-rank tests. Patient death was identified using the SRTR, which is linked to the Social Security Master File and confirmed through clinician report. Graft failure was identified as any reported graft failure or death (ie, "all-cause graft loss"). Recipients were censored upon retransplantation or multiorgan transplantation (eg, liver-kidney).
We used Cox proportional hazards models to characterize the association between allograft type and graft and patient survival after adjustment for recipient weight at transplant, recipient age at transplant, sex, race/ethnicity, underlying disease, allocation PELD/MELD at transplant, status 1 designation, donor age, cold ischemia time, and insurance type; sensitivity analysis with laboratory PELD/MELD scores and exception status were also performed, and did not influence findings. Additional sensitivity analysis with transplant region was assessed using shared frailty modelling were reported. 12 The decision to include these specific variables in the final model for multivariable regression was derived from associations between covariates with risk factors and the outcome in both the published literature as well as statistical tests (eg, c 2 , ANOVA) within this cohort.
To characterize changes in unadjusted patient and graft survival over time, 30-day and 1-year survival between allograft types were further stratified by time period of transplantation (ie, 2002-2009 vs 2010-2015) . We used an interaction term analysis to determine whether the association between allograft type and adjusted patient and graft survival varied over time period.
We tested whether the hazard associated with patient survival after SLT, LDLT, and WLT varied over follow-up time using a time-binned analysis and estimated the hazard associated with each allograft type within the first 30 days after transplantation (ie, early) and after the first 30 days after transplantation (ie, late).
Statistical Analyses
All statistical tests used a 2-sided a of 0.05. Categorical variables were compared using a c 2 test and continuous variables were compared using ANOVA. CIs are reported using the method of Louis and Zeger, as previously reported. 13 All analyses were performed using STATA 14.0 (College Station, Texas). This study was approved by the Institutional Review Board of Johns Hopkins University School of Medicine.
Results
Among the 5715 children who underwent liver transplantation, 3428 (60%) received a WLT, 1626 (28.5%) a SLT, and 661 (11.6%) an LDLT ( Table I ; available at www.jpeds.com). SLT and LDLT recipients were more likely to be under 2 years of age and to weigh less than 10 kg (P < .001 for both age and weight). African Americans were less likely than Caucasians to undergo LDLT, and more likely to receive a whole graft (P < .001). LDLT recipients were more likely to have had biliary atresia (P < .001). The donor age for nearly all individuals receiving a living donor was 18-50 years of age, whereas WLT recipients were more likely to have donors age 0-17 years of age (P < .001). PELD/MELD scores at transplantation were lower in LDLT (P < .001), and SLT recipients were more likely to be status 1 than WLT and LDLT recipients (P < .001). The mean cold ischemia time was shortest for LDLT (P < .001). LDLT recipients were more likely to have private insurance and SLT recipients were more likely to have public insurance (P < .001).
From 2002-2009 to 2010-2015, the frequency of transplants was similar for WLT (60% for both), SLT (29% and 28%), and LDLT (11% and 12%; P = .6). The frequency of Volume 196 • May 2018 reduced SLT (ie, "cut-down"), where only 1 portion was used, was the same for both periods (13.2% and 13.6%). Among 104 centers performing any type of liver transplant, 66 centers (63%) performed at least 1 SLT over the entire study period, and 8 (8%) performed at least 1 SLT each year. Fifty-seven (55%) centers performed at least 1 LDLT over the entire study period, and 4 (4%) centers performed at least 1 LDLT per year.
Short-Term Patient Survival
Since the PELD/MELD system was implemented in 2002, the unadjusted 30-day patient survival across all allograft types was 97%, and was significantly lower in SLT compared with WLT (96% vs 98%; P < .001), and survival for LDLT and WLT was similar (98% for both; P = .4; Table II 
Long-Term Patient Survival
Patient survival at 1 year was 94% for all pediatric recipients over the study period and significantly lower for SLT compared with WLT (92% vs 95%; P = .002), but similar for LDLT and WLT (96% vs 95%; P = .2). The relative impact of allograft type on short-term survival varied by time period. From 2002 to 2009, survival after SLT was worse than WLT (89% vs 94%; P < .001), whereas no difference was observed from 2010 
Graft Survival
The overall unadjusted 30-day graft survival was 93% (Table IV and Figure 2 ; available at www.jpeds.com). Only SLT showed significant improvement from 2002-2009 to 2010-2015 (90% vs 93%; P = .01), whereas no improvement was seen in WLT (92% vs 93%; P = .1) or LDLT (94% vs 95%; P = .6). Graft survival at 1 year improved for SLT (85% vs 90%; P = .002) and LDLT (89% vs 94%; P = .03), but not WLT (89% vs 90%; P = .14). In an adjusted model, the association between allograft type and graft survival did not vary by time period (P > .05 for interaction coefficients) and, thus, overall estimates are reported instead. Additionally, the hazard of graft failure was proportionally constant throughout the followup period; therefore, early and late graft failure were not evaluated separately. 
Additional Risk Factors for Death and Graft failure
In a multivariable model, several other characteristics were associated with both death and graft failure (Table VI; available at www.jpeds.com). Acute hepatic necrosis, malignancy, and status 1 designation were associated with increased death and graft loss, as was public insurance and donor age greater than 50 years of age. Recipient race/ethnicity, weight, and allocation score at transplantation were not associated with death or graft failure. Although recipient age was not associated with death, children 2-12 years of age had lower graft loss than children less than 2 years of age. Years 2010-2015 overall were associated with lower death and graft loss. 
Regional Variation

Discussion
In this national study examining trends in pediatric liver transplantation since the implementation of the PELD/MELD system, several important findings were evident with respect to the relationship between allograft type and patient and graft survivals. First, although overall outcomes have improved, these improvements can be largely attributed to improvements in early outcomes after SLT, as well as to improvements in longterm outcomes after SLT and LDLT; outcomes after WLT have been largely unchanged since the current PELD/MELD system was implemented. Second, poor outcomes for SLT were initially due to increased early death, but this problem is no longer evident, such that risk of early death in SLT has decreased, and is similar to WLT. Finally, graft survival for LDLT was superior to WLT. Collectively, these findings suggest that the increasing experience with technical variant grafts such as SLT and LDLT have coincided with improved patient and graft survivals. Our analysis also identifies several important risk factors for death and graft failure in this large cohort, including notable findings that better outcomes may be seen in biliary atresia, as well as lower rates of graft failure in children between 2 and 12 years of age. Additionally, although all race and ethnic groups had comparable outcomes, higher rates of death and graft loss were seen in individuals with public insurance. These findings are consistent with other challenges facing individuals in the pediatric liver transplant community with public insurance, such as higher rates of waitlist mortality and a lesser likelihood of obtaining exception points. 14, 15 Reports on the impact of allograft type in pediatric liver transplantation have been conflicting. The Studies of Pediatric Liver Transplantation (SPLIT) consortium of 44 pediatric centers examined a range of outcomes on recipients from 1995 to 2006 and found increased graft failure in SLT, but not LDLT, when compared with WLT in an unadjusted model. 8 These authors also reported higher rates of complications requiring surgical revision in both SLT and LDLT compared with WLT. A second study from the SPLIT consortium showed increased death and graft loss for both technical variant grafts. 16 A large, singlecenter study of recipients between 1993 and 2006 similarly found a higher risk of mortality and graft failure in SLT, but not LDLT. 9 Other studies derived from the United Network for Organ Sharing (UNOS) and SRTR registries before the implementation of PELD/MELD have shown a general tendency for SLT to have worse patient and graft survival, whereas LDLT may have superior or equivalent outcomes compared with WLT. 17, 18 At the same time, some studies have suggested that allograft ORIGINAL ARTICLES type does not affect outcomes. Austin et al looked at outcomes in UNOS from as early as 1987-2004 and showed no difference in patient and graft survival by allograft type, but this finding may be driven by relatively poor outcomes in this cohort from all transplants in the early years of the cohort. For example, the authors report an overall 1-year patient survival of 83% compared with 94% in our study. 19 Finally, in the most recent study from SRTR that evaluated patient and graft survival in a limited cohort of children under 12 years old from 2002 to 2004, there was no variability in outcomes by allograft type. 10 Our finding that overall patient and graft survivals after pediatric liver transplantation have improved over time is broadly consistent with other studies. 20, 21 One large study derived from the UNOS database from 1995 to 2010 of children showed that patient and graft survival improved from 1995-2000 to 2006-2010, but saw similar results between 2001-2005 and the end of the study period. 20 This study was limited to children under 2 years of age who received a whole or deceased split graft, and because it spanned the implementation of PELD/MELD, it was not possible to adjust for the score or status 1 designation and authors used intensive care unit and ventilator status instead. They also tested for interaction between eras and allograft status and showed a trend toward improved relative hazard after SLT compared with WLT, but the interaction between era and allograft type was not significant for patient or graft survival. Here, we demonstrated overall improvement since PELD/ MELD was implemented and across all pediatric age groups. Furthermore, we showed significant improvement in the most recent transplant period (ie, 2010-2015) , such that outcomes after SLT are now similar to WLT.
An important consideration when discussing increased adoption of SLT is the impact on the adult recipient who might otherwise receive a whole graft, especially because SLT has been seen as contributing to a donor risk index in some, but not all, adult studies. 22, 23 A recent study of the UNOS database looking at adult SLT recipients reported similar findings that patient and graft survival have improved over time and are now similar to WLT. 7 At the same time, increased vascular and biliary complications continue to be reported in technical variant donation relative to WLT, and an important limitation of our study was that we were unable to explore these additional complications. 16, 24, 25 Although the use of these grafts will increase the organ supply, allow for earlier transplantation, and potentially decrease total costs, at the same time, complications from these grafts are likely to be associated with longer durations of stay and greater costs in the perioperative period. 3, 25, 26 Given the current need to optimize outcomes and reduce costs (ie, increase value), the decision to use these organs by transplant teams, and to advocate for greater use through policy, will require a better understanding of the frequency of these complications and how these complications impact care from a number of perspectives. 27 Nonetheless, some centers have incorporated practices where SLT is prioritized, and have been able to achieve the competing goal of good long-term outcomes alongside the benefits of increased organ supply. 28 Another limitation of our study was that it was derived from an observational cohort as opposed to an experimental study.
Although the finding that overall outcomes have improved over time should be expected, it is difficult to know whether the decision by the transplant team to perform a specific type of transplant is a reflection of their assessment of the patient's disease severity, surgical experience, or some other factor; if SLT was only performed when the patient was perceived to be relatively stable, this decision might influence the observed outcomes. One advantage of our study is that it is conducted exclusively in the PELD/MELD era, and we adjusted for the score at transplant as well as exception status, a well-validated tool for assessing medical severity. Consequently, the relative effects that were seen in the multivariable model that adjusted for score and exception status should account for the impact of disease severity. Although it is possible that the improvement seen in SLT can be attributed to unmeasured or residual confounding of disease severity that coincides with a shift in clinical practice and decision making, our evidence nonetheless suggests that a group of children can do well with SLT, and that more research should be performed to identify the specific patient, donor, and surgical characteristics that yield good outcomes.
Finally, it should be noted that there can be errors in reporting from studies derived from national registries, such as patients being incorrectly classified as dead or with graft failure. However, these errors should be minimal, if they exist at all, given that the SRTR verifies death with the Social Security Master File and that graft failure must be accurately identified in the registry for a patient to receive a new liver.
Given shortages in organ supply, there is continued interest and effort in identifying additional opportunities to expand the supply, including the use of extended criteria donors, donation after cardiac death, and technical variant donation. 6, [29] [30] [31] Children may be particularly vulnerable to decreased supply, with a recent report suggesting that nearly one-half of all children who died awaiting transplantation had not received a single offer of a liver, with a median offer number of 1.
14 Size mismatch was identified in nearly one-third of patients as a reason offers were not accepted, although nearly one-half may have actually been an appropriate size, suggesting the potential for greater use of split transplantation in reducing waitlist mortality. Our national study of more than 5000 pediatric liver transplant recipients provides strong evidence that allograft type no longer predicts patient and graft survival in this population. These findings have the potential to substantially influence policy for allocation of deceased organs to children in need. Given that children comprise a relatively small percentage of people on the national waitlist, increased use of SLT might provide an optimal way to increase the supply for children, without placing them at risk for worse outcomes, so that pretransplant mortality and morbidity can be minimized. 
